Tango Therapeutics TNGX 深 沪
等待开盘 09-17 09:30:00 美东时间
23.35
-0.540
-2.26%
华盛通- 最 高24.39
- 今 开24.17
- 成交量 283.53万股
- 最 低 23.00
- 昨 收 23.89
- 总市值 39.37亿
- 52周最高 34.39
- 市盈率 静 --
- 换手率 1.68%
- 52周最低 6.69
- 委 比 77.25%
- 总股本 1.69亿
- 历史最高 34.39
- 量 比 1.00
- 振 幅 5.82%
- 历史最低 1.03
- 每 手 1
- 风险率 8.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling around 400 points on Wednesday. Shares of Caleres Inc (NYSE:CAL) rose sharply after the company reported better-than-expected second-quarter financial results and raised its FY26 EPS guidance. Caleres reported quarterly earnings of 47 cents pe...
09-09 22:04
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics granted a new employee 146,500 stock options and 40,000 RSUs under its 2023 Inducement Plan. The options have an exercise price of $22.35 per share, vesting 25% after the first year and monthly thereafter, while RSUs vest annually over three years. The company focuses on precision cancer medicine using synthetic lethality principles.
09-03 20:05
Most shorted stocks on Wall Street
As September begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 44 stocks with short interest above 20% ...
09-02 22:28
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35
Guggenheim analyst Michael Schmidt maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $32 to $35.
08-12 20:24
Tango Therapeutics Q2 EPS $(0.37) Misses $(0.32) Estimate
Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.32) by 15.62 percent. This is a 5.71 percent decrease over losses of $(0.35) per share from the same period last year.
08-11 19:27
美股大行评级 | 台积电、联合健康、美国合众银行获多家大行上调目标价；奈飞、直觉外科遭数十家大行下调目标价
今日重点评级关注：摩根大通：维持联合大陆航空"超配"评级，目标价从156美元升至203美元；摩根士丹利：维持联合大陆航空"超配"评级，目标价从185美元升至190美元
07-20 13:49
美股大行评级 | 潜在涨幅284.62%！Annexon获Needham上调目标价至25美元；多家大行上调美国银行目标价
今日重点评级关注：Needham：维持Annexon"买入"评级，目标价从11美元升至25美元；Benchmark：维持Prenetics Global"买入"评级，目标价从30美元升至40美元
07-16 18:55
JP Morgan Initiates Coverage On Tango Therapeutics with Overweight Rating, Announces Price Target of $46
JP Morgan analyst Brian Cheng initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating and announces Price Target of $46.
07-15 18:40
